clinical trial · NCT07867938
A Clinical Trial of Tulisokibart (MK-7240) in Participants With Pulmonary Sarcoidosis (MK-7240-016)
Merck Sharp & Dohme LLC·phase2·recruiting·n = 158
Pulmonary SarcoidosisTulisokibartPlaceboBackground prednisone therapy
brief summary
Researchers are looking for new ways to treat active pulmonary sarcoidosis (PS). This trial will help researchers learn if a trial medicine called tulisokibart can treat symptoms of active PS. The goal of this trial is to learn if tulisokibart works better than placebo to increase the length of time until PS gets worse.
started
Nov 3, 2026
primary completion
Oct 5, 2029
completion
Jan 11, 2030
last updated
Nov 16, 2026
official title
A Phase 2 Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Tulisokibart in Participants With Active Pulmonary Sarcoidosis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol